Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinson’s Disease
暂无分享,去创建一个
Christine Klein | Karen Marder | Luis Carrillo-Reid | Li Chen | Dimitri Krainc | John Q Trojanowski | D James Surmeier | Maria Sundberg | Lorraine Clark | Ole Isacson | Hyemyung Seo | D. Surmeier | J. Trojanowski | K. Marder | V. Lee | D. Krainc | R. Uitti | G. Opala | L. Carrillo-Reid | Z. Wszolek | Jian Feng | T. Dawson | V. Dawson | L. Clark | O. Isacson | C. Klein | M. Sundberg | S. Przedborski | T. Lawson | C. Moskowitz | O. Ross | Zhong Xie | M. Deleidi | L. Volpicelli-Daley | C. Guardia-Laguarta | H. Seo | J. McLean | Laura Volpicelli-Daley | Valina L Dawson | Ted M Dawson | Ryan J Uitti | Grzegorz Opala | Virginia M-Y Lee | Owen A Ross | Zbigniew K Wszolek | Serge Przedborski | Helle Bogetofte | S. Andrabi | Houbo Jiang | Li Chen | Jian Feng | N. Romero | Joseph R. Mazzulli | Zhigao Huang | Joseph Mazzulli | Carol Moskowitz | Oliver Cooper | Shaida Andrabi | Cristina Guardia-Laguarta | John Graziotto | Jesse R McLean | Zhong Xie | Teresia Osborn | Gunnar Hargus | Michela Deleidi | Tristan Lawson | Helle Bogetofte | Eduardo Perez-Torres | Norma Romero | Houbo Jiang | Leslie A Scarffe | G. Hargus | J. Graziotto | J. Mazzulli | O. Cooper | Leslie Scarffe | T. Osborn | E. Pérez-Torres | Zhigao Huang | Hyemyung Seo | Luis Carrillo-Reid | Norma Romero
[1] Ted M. Dawson,et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy , 2009, Proceedings of the National Academy of Sciences.
[2] E. Tolosa,et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.
[3] Jussi Taipale,et al. Small molecule modulation of Smoothened activity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[4] Sonja W. Scholz,et al. Genome-Wide Association Study reveals genetic risk underlying Parkinson’s disease , 2009, Nature Genetics.
[5] O. Isacson,et al. Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid , 2010, Molecular and Cellular Neuroscience.
[6] J. Langston,et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.
[7] J. Hardy,et al. Genetic Analysis of Pathways to Parkinson Disease , 2010, Neuron.
[8] Lloyd A Greene,et al. Rapamycin Protects against Neuron Death in In Vitro andIn Vivo Models of Parkinson's Disease , 2010, The Journal of Neuroscience.
[9] O. Isacson,et al. Development of Histocompatible Primate‐Induced Pluripotent Stem Cells for Neural Transplantation , 2011, Stem cells.
[10] F. Gillardon. Leucine‐rich repeat kinase 2 phosphorylates brain tubulin‐beta isoforms and modulates microtubule stability – a point of convergence in Parkinsonian neurodegeneration? , 2009, Journal of neurochemistry.
[11] D. Brooks. Examining Braak's hypothesis by imaging Parkinson's disease , 2010, Movement disorders : official journal of the Movement Disorder Society.
[12] Paul T. Schumacker,et al. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1 , 2010, Nature.
[13] L. Rubin. Stem Cells and Drug Discovery: The Beginning of a New Era? , 2008, Cell.
[14] Hynek Wichterle,et al. A functionally characterized test set of human induced pluripotent stem cells , 2011, Nature Biotechnology.
[15] G. Daley,et al. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells , 2009, Nature Biotechnology.
[16] Ajit S. Divakaruni,et al. The regulation and physiology of mitochondrial proton leak. , 2011, Physiology.
[17] D. Krainc,et al. Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells , 2011, The Journal of Neuroscience.
[18] Ruslan I. Dmitriev,et al. Bafilomycin A1 activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondria , 2010, Cellular and Molecular Life Sciences.
[19] Kristopher L. Nazor,et al. Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.
[20] M. Vila,et al. Pathogenic Lysosomal Depletion in Parkinson's Disease , 2010, The Journal of Neuroscience.
[21] N. Hattori,et al. PARK6-linked autosomal recessive early-onset parkinsonism in Asian populations , 2004, Neurology.
[22] B. Ames,et al. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[23] H. Kawamata,et al. Mutant SOD1 in neuronal mitochondria causes toxicity and mitochondrial dynamics abnormalities. , 2009, Human molecular genetics.
[24] A. Lang,et al. The curious case of phenocopies in families with genetic Parkinson's disease , 2011, Movement disorders : official journal of the Movement Disorder Society.
[25] Andrew Lees,et al. Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.
[26] N. Brustovetsky,et al. Stimulation of glutamate receptors in cultured hippocampal neurons causes Ca2+-dependent mitochondrial contraction. , 2009, Cell calcium.
[27] M. Toft,et al. CORTICOBASAL SYNDROME AND PRIMARY PROGRESSIVE APHASIA AS MANIFESTATIONS OF LRRK2 GENE MUTATIONS , 2008, Neurology.
[28] Thomas Meitinger,et al. Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.
[29] J. Jankovic,et al. Genetic analysis of LRRK2 mutations in patients with Parkinson disease , 2006, Journal of the Neurological Sciences.
[30] C. Ross,et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[31] D. Maraganore,et al. A Genomic Pathway Approach to a Complex Disease: Axon Guidance and Parkinson Disease , 2007, PLoS genetics.
[32] H. Wichterle,et al. Small-molecule modulators of Hedgehog signaling: identification and characterization of Smoothened agonists and antagonists , 2002, Journal of biology.
[33] Margaret A. Pericak-Vance,et al. Identifying Consensus Disease Pathways in Parkinson's Disease Using an Integrative Systems Biology Approach , 2011, PloS one.
[34] Nobutaka Hattori,et al. Novel PINK1 mutations in early‐onset parkinsonism , 2004, Annals of neurology.
[35] J. Trojanowski,et al. Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.
[36] N. Brüggemann,et al. Mutations in PINK1 and Parkin Impair Ubiquitination of Mitofusins in Human Fibroblasts , 2011, PloS one.
[37] C. Geula,et al. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons , 2006, Nature Genetics.
[38] A. Davies,et al. Parkinson's disease α-synuclein mutations exhibit defective axonal transport in cultured neurons , 2004, Journal of Cell Science.
[39] P. C. Chin,et al. The c‐Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK‐ERK and Akt‐independent mechanism , 2004, Journal of neurochemistry.
[40] R. Nussbaum,et al. Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.
[41] M. Ripoli,et al. Mitochondrial Respiratory Dysfunction in Familiar Parkinsonism Associated with PINK1 Mutation , 2008, Neurochemical Research.
[42] Ole Isacson,et al. CD15, CD24, and CD29 Define a Surface Biomarker Code for Neural Lineage Differentiation of Stem Cells , 2009, Stem cells.
[43] A. Whitworth,et al. Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss , 2009, Nature Neuroscience.
[44] C. C. Johnson,et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living , 1998, Neurology.
[45] R. Llinás,et al. 1-Methyl-4-phenylpyridinium affects fast axonal transport by activation of caspase and protein kinase C , 2007, Proceedings of the National Academy of Sciences.
[46] I. König,et al. Biological effects of the PINK1 c.1366C>T mutation: implications in Parkinson disease pathogenesis , 2007, Neurogenetics.
[47] Ling Lin,et al. Cell type-specific gene expression of midbrain dopaminergic neurons reveals molecules involved in their vulnerability and protection. , 2005, Human molecular genetics.
[48] C. Chu,et al. Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization. , 2011, Human molecular genetics.
[49] L. Goldstein,et al. Microtubule-based transport systems in neurons: the roles of kinesins and dyneins. , 2000, Annual review of neuroscience.
[50] Ole Isacson,et al. Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.
[51] K. Altendorf,et al. Inhibitory effect of modified bafilomycins and concanamycins on P- and V-type adenosinetriphosphatases. , 1993, Biochemistry.
[52] T. Nishi,et al. The vacuolar (H+)-ATPases — nature's most versatile proton pumps , 2002, Nature Reviews Molecular Cell Biology.
[53] M. Salkinoja-Salonen,et al. Bafilomycin A1 is a potassium ionophore that impairs mitochondrial functions , 2007, Journal of bioenergetics and biomembranes.
[54] M. Farrer,et al. Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. , 2006, Archives of neurology.
[55] K. Lohmann,et al. Clinical and demographic characteristics of PINK1 mutation carriers—A meta‐analysis , 2010, Movement disorders : official journal of the Movement Disorder Society.
[56] Alan Colman,et al. Pluripotent stem cells and disease modeling. , 2009, Cell stem cell.
[57] J. Trojanowski,et al. Corticobasal syndrome and primary progressive aphasia as manifestations of LRRK2 gene mutations , 2008, Neurology.
[58] A. Bentivoglio,et al. Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. , 2001, American journal of human genetics.
[59] L. Greene,et al. RTP801 Is Induced in Parkinson's Disease and Mediates Neuron Death by Inhibiting Akt Phosphorylation/Activation , 2008, The Journal of Neuroscience.
[60] Mathias Toft,et al. Clinical features of LRRK2‐associated Parkinson's disease in central Norway , 2005, Annals of neurology.
[61] M. Cookson,et al. Parkinson's disease: insights from pathways. , 2010, Human molecular genetics.
[62] F. Binkofski,et al. Clinical spectrum of homozygous and heterozygous PINK1 mutations in a large German family with Parkinson disease: role of a single hit? , 2006, Archives of neurology.
[63] Krishanu Saha,et al. Technical challenges in using human induced pluripotent stem cells to model disease. , 2009, Cell stem cell.
[64] Mark R. Cookson,et al. The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.
[65] D W Dickson,et al. Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.
[66] Robert W. Taylor,et al. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease , 2006, Nature Genetics.
[67] K. Lohmann,et al. Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients. , 2010, Human molecular genetics.
[68] H. Mortiboys,et al. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2 , 2010, Neurology.
[69] A. Graybiel,et al. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. , 1999, Brain : a journal of neurology.